171 related articles for article (PubMed ID: 33935538)
1. Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation.
Hacisalihoglu UP; Sahin D
Sisli Etfal Hastan Tip Bul; 2021; 55(1):68-75. PubMed ID: 33935538
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.
Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L
Ann Hematol; 2019 Aug; 98(8):1867-1875. PubMed ID: 30993415
[TBL] [Abstract][Full Text] [Related]
3. Lichen planus-like histopathologic characteristics in the cutaneous graft-vs-host reaction. Prognostic significance independent of time course after allogeneic bone marrow transplantation.
Horn TD; Zahurak ML; Atkins D; Solomon AR; Vogelsang GB
Arch Dermatol; 1997 Aug; 133(8):961-5. PubMed ID: 9267240
[TBL] [Abstract][Full Text] [Related]
4. Survey of European Blood and Marrow Transplant (EBMT) nurses to explore the current topical skin management of chronic cutaneous graft versus host disease in the real-world clinical environment.
Murray J; Liptrott S; Canesi M; Mooyaart J; Kisch A; Piepenbroek B; Stringer J
Eur J Oncol Nurs; 2024 Apr; 69():102547. PubMed ID: 38467081
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous graft-versus-host disease].
Karrer S
Hautarzt; 2003 May; 54(5):465-80; quiz 481-2. PubMed ID: 12833893
[TBL] [Abstract][Full Text] [Related]
6. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
7. Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation.
Kaminska-Winciorek G; Zalaudek I; Mendrek W; Jaworska M; Gajda M; Hołowiecki J; Szymszal J; Giebel S
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1043-1061. PubMed ID: 32676797
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.
Milgrom SA; Nieto Y; Pinnix CC; Smith GL; Wogan CF; Rondon G; Medeiros LJ; Kebriaei P; Dabaja BS
J Med Case Rep; 2016 Jul; 10():209. PubMed ID: 27465468
[TBL] [Abstract][Full Text] [Related]
9. The histological diagnosis of cutaneous graft versus host disease: relationship of skin changes to marrow purging and other clinical variables.
Elliott CJ; Sloane JP; Sanderson KV; Vincent M; Shepherd V; Powles R
Histopathology; 1987 Feb; 11(2):145-55. PubMed ID: 3552928
[TBL] [Abstract][Full Text] [Related]
10. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
[TBL] [Abstract][Full Text] [Related]
11. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients.
Fischer A; Jakubowski AA; Lacouture ME; Hollmann TJ; Drucker AM; Maloy M; Prockop S; Querfeld C; Busam KJ; Pulitzer MP
Am J Dermatopathol; 2015 Jul; 37(7):523-9. PubMed ID: 26091510
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Graft-Versus-Host Disease and Survival in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience.
Bedir Demirdağ T; Kurşun Ağlamiş G; Kirkiz Kayal S; Uğraş Dikmen A; Kaya Z; Yenicesu İ; Koçak Ü
Exp Clin Transplant; 2021 Nov; ():. PubMed ID: 34775938
[TBL] [Abstract][Full Text] [Related]
18. Sequential immunohistologic analysis of the skin following allogeneic bone marrow transplantation.
Volc-Platzer B; Rappersberger K; Mosberger I; Hinterberger W; Emminger-Schmidmeier W; Radaszkiewicz T; Wolff K
J Invest Dermatol; 1988 Aug; 91(2):162-8. PubMed ID: 3294303
[TBL] [Abstract][Full Text] [Related]
19. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous manifestations of graft versus host disease in a population of pediatric and young adults patients].
Martino C; Calvano R; Boggio P; Scacchi MF; Sojo M; Carbajosa A; Makiya M; Giachetti A
Arch Argent Pediatr; 2020 Oct; 118(5):e468-e475. PubMed ID: 32924403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
